hVIVO plc (HVO), a purpose-built, full-service international clinical development partner and the world leader in human challenge trials, announced its unaudited interim results for the six months ended 30 June 2026.
hVIVO plc (HVO), a purpose-built, full-service international clinical development partner and the world leader in human challenge trials, announced its unaudited interim results for the six months ended 30 June 2026.
UK equities rallied strongly on Friday as investors responded positively to growing optimism that a diplomatic agreement between the United States and Iran could be within reach, easing concerns over
Thor Energy plc (AIM: THR, ASX: THR) has reported highly encouraging preliminary results from its Phase-2 soil air geochemistry programme at the HY-Range Natural Hydrogen Project in South Australia, with
The FTSE 100 edged lower on Friday, closing down around 15 points at just under 10,364. The FTSE 250 showed a more positive tone heading into the bank holiday, rising
Halfords Group plc (HFD), the UK’s leading provider of motoring and cycling products and services, is pleased to provide a strong trading update ahead of its FY26 results. Group like-for-like (“LfL”)
HUI (HUI), a pioneering company converting non-recyclable mixed waste plastic, tyres and hazardous waste materials into hydrogen and carbon-free fuels, announced that it has identified the potential to use the InEnTec
Georgina Energy (GEX) said further to the Company’s announcement of 30 October 2025, concerning the receipt of formal approval from the Western Australian Department of Mining, Petroleum and Explorationto drill the
Daily Mail: Labour’s first ‘one-in, one-out’ migrant deportation to France ‘is abandoned after last-minute legal challenge’
Catenai (CTAI), the AIM quoted provider of digital media and technology, noted the “First Look” event in London held by Alludium Ltd on 3 July 2025. The event featured an overview
Catenai (CTAI), the AIM quoted provider of digital media and technology, announced that Alludium Ltd will be hosting an in-person ‘First Look’ event in London on 3 July 2025.
Avacta Therapeutics (AVCT), a life sciences company developing next generation peptide drug conjugates (PDC) targeting powerful anti-tumor payloads directly to the tumor, announced preclinical results from its second pre|CISION® candidate FAP-EXd
While we wonder what the point of financial platforms / journalists / PR merely copying and pasting or telling us what we can already read, here are the RNS highlights